HLB unveils roadmap for novel drugs for 3 cancer types by 2026

The Korea Times - Feb 12, 2025

Korean pharmaceutical company HLB unveiled its roadmap for adding novel anticancer treatments for three cancer types to its portfolio by 2026, as part of its bid to cement its position as an oncology-focused specialist following the anticipated U.S. approval of its targeted anticancer treatment, Rivoceranib, next month.

Read full article

More News

Scienfinite

Scienfinite publishes articles with a unique approach to inspire our readers with the aim to understand the world and appreciate its everyday awe.